Akero Therapeutics Inc Cash Flow-to-Debt Ratio
Akero Therapeutics Inc cash flow-to-debt ratio. Akero Therapeutics Inc (AKRO) has a Cash Flow-to-Debt Ratio of -1.40x as of September 2025, meaning its operating cash flow of $-67.17 Million could theoretically repay -1% of its total liabilities ($47.94 Million) in one year. See Akero Therapeutics Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Akero Therapeutics Inc (2017–2024)
Cash flow-to-debt ratio of Akero Therapeutics Inc from 2017 to 2024. Historical debt coverage capacity for Akero Therapeutics Inc across 8 annual periods. Also explore how fast is Akero Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Akero Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2024)
Akero Therapeutics Inc cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Akero Therapeutics Inc. For the full cash flow conversion analysis, see Akero Therapeutics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.04x | $-230.11 Million | $75.77 Million | ▲ +6.1% |
| 2023 | -3.23x | $-145.37 Million | $44.97 Million | ▼ -4.9% |
| 2022 | -3.08x | $-92.52 Million | $30.01 Million | ▼ -2.3% |
| 2021 | -3.01x | $-79.68 Million | $26.44 Million | ▲ +37.7% |
| 2020 | -4.84x | $-70.80 Million | $14.63 Million | ▼ -27.6% |
| 2019 | -3.79x | $-35.63 Million | $9.39 Million | ▼ -10322.0% |
| 2018 | -0.04x | $-4.62 Million | $127.07 Million | ▲ +95.7% |
| 2017 | -0.84x | $-4.38 Million | $5.22 Million | — |